SUBSCRIBE
SUBSCRIBE

Nick Paul Taylor

Nick is a freelance writer who has been reporting on the global life sciences industry since 2008. With a BSc in biology, Nick writes about the science and business of biopharma and medtech for numerous healthcare publications. He can be reached at nick.paul.taylor@gmail.com or on LinkedIn.

Shanghai,China-August 24th 2025: AstraZeneca company office building
Earnings
AstraZeneca bullish on $80B sales goal after beating expectations, Phase 3 data wins
After a quarter in which sales topped $15 billion and key readouts went AstraZeneca’s way, the company is increasingly confident that its 2030 revenue target is in reach.
April 29, 2026
 · 
2 min read
 · 
Nick Paul Taylor
Recovering losses, effective economic measures to help alleviate inflation or economic crisis resulting in the collapse of the business economy or stock market, helping hands to catch gold coins rolling down a tilted cliff
Patents
Pfizer settles with generic drugmakers to protect blockbuster drug until 2031
The settlements delay the entry of generic copies of Pfizer’s Vyndamax by almost three years, stabilizing sales of a drug that generated $3.8 billion in the U.S. last year.
April 29, 2026
 · 
2 min read
 · 
Nick Paul Taylor
Sanofi CEO Belén Garijo
C-suite
Garijo starts as Sanofi CEO with window to ease reliance on Dupixent
The new CEO has at least five years and a large M&A war chest to position Sanofi for life after the loss of exclusivity on its cornerstone immunology product.
April 28, 2026
 · 
4 min read
 · 
Nick Paul Taylor
scientists couple holding barrels with warning sign african american man woman in protective suits working with chemicals research science concept modern laboratory interior full length horizontal vector illustration..
Manufacturing
UCSF, Par Health hit with FDA warning letters for environmental monitoring issues
FDA inspectors warned UCSF radiopharmaceutical facility that losing environmental control could pose a serious hazard to patients.
April 27, 2026
 · 
2 min read
 · 
Nick Paul Taylor
Illustration of two arrows merging into one
Deals
Amneal inks $1.1B Kashiv buyout to pursue biosimilar market leadership
The takeover will give Amneal control of four facilities to manufacture biosimilars for a planned wave of launches in the coming years.
April 23, 2026
 · 
2 min read
 · 
Nick Paul Taylor
USA Map with red pins featuring the Carolinas, specifically Raleigh Durham. Could be used to showcase store locations or represent many locations.
Manufacturing
AbbVie commits $1.4B to NC plant in its largest-ever single campus investment
The Durham plant will manufacture immunology, neuroscience and oncology drugs once AbbVie finishes construction in 2028.
April 23, 2026
 · 
2 min read
 · 
Nick Paul Taylor
3D Yellow triangle warning sign symbol on yellow background. Emergency alert, and caution. Illustration with copy space
Manufacturing
FDA issues warning letter after GLP-1 manufacturer refuses inspectors access
New Life told FDA inspectors that they lacked the authority to enter parts of a facility where it made the GLP-1 receptor agonists semaglutide and tirzepatide.
April 22, 2026
 · 
2 min read
 · 
Nick Paul Taylor
Brain shaped maze. Conceptual image of science and medicine. 3D illustration.
rare diseases
Ionis’ antisense drug stabilizes ultra-rare disease ahead of FDA decision
The pivotal study of zilganersen in Alexander disease missed a secondary endpoint, but analysts expect the FDA to approve the asset given the unmet need and overall data.
April 22, 2026
 · 
2 min read
 · 
Nick Paul Taylor
Close up of a pile of cardboard boxes. They have been stamped "Defective Product" and "Product Recalled". The boxes are bathed in soft yellow neutral lighting.
Manufacturing
Viatris recalls extended-release Xanax over dissolution test failure
Viatris, which Pfizer created in 2020, voluntarily withdrew extended-release products made at a plant in Ireland after an analysis revealed an issue that could affect bioavailability.
April 20, 2026
 · 
2 min read
 · 
Nick Paul Taylor
Sunset illuminating the tall skyscrapers of San Diego in California from Centennial Park in Coronado
Cancer
Merck’s PD-1/VEGF data star in stacked lineup of AACR ‘26 data reveals
The Merck update, which will shed light on a $588 million bet to succeed Keytruda, is part of a roster of presentations that could shape the future of ADCs, protein degraders and KRAS-targeted therapies.
April 17, 2026
 · 
5 min read
 · 
Nick Paul Taylor
FDA signage at its headquarters in Maryland
FDA
FDA mulls compounding for peptides previously flagged over safety risks
With Health Secretary Robert F. Kennedy Jr. declaring himself “a big fan of peptides,” the FDA has arranged an advisory committee to discuss allowing compounders to make molecules despite earlier safety concerns.
April 16, 2026
 · 
1 min read
 · 
Nick Paul Taylor
Globe and stack with coins. Money makes the world go round
Manufacturing
Lilly investing billions to prepare for overseas oral GLP-1 launches
With many overseas patients preferring orals to injectables, Eli Lilly has filed for approval of orforglipron in more than 40 countries and is building manufacturing capacity to support the obesity drug.
April 14, 2026
 · 
2 min read
 · 
Nick Paul Taylor
Aerial view of cargo ship terminal
Manufacturing
USP adds Tamiflu, Trulicity to vulnerable list as upstream analysis reshapes supply concerns
Almost half of the top 100 medicines vulnerable to supply disruptions in the U.S. have at least one key starting material with a single source country, according to a new report from United States Pharmacopeia.
April 13, 2026
 · 
2 min read
 · 
Nick Paul Taylor
Business teamwork and partnership help to achieve team success, think together to solve business problem, business connection concept, businessmen working team building connect jigsaw puzzle bridge.
FDA
FDA’s CRL transparency policy is boosting biopharma accountability
Since the FDA began publishing its rejections of drug approval filings in July last year, companies have become more forthcoming about the details of agency decisions in their own disclosures, according to biopharma and regulatory analysts.
April 13, 2026
 · 
5 min read
 · 
Nick Paul Taylor
Chemistry creative concept. Circle frame with icons. Flag of China
Manufacturing
Innovent’s CDMO gets green light to make biologics at large Chinese plant
The license, which Innovent’s Altruist business said is the first of its kind, positions the CDMO to support commercial clients as it works to expand the plant’s capacity to 172,000 liters.
April 9, 2026
 · 
2 min read
 · 
Nick Paul Taylor
Load More